Внутрикорпоративная торговля на американском рынке | MiMedx Group раскрыла 2 факта о сделках внутренних лиц 17 марта

robot
Генерация тезисов в процессе

17 March 2026, MiMedx Group (MDXG) disclosed two transactions involving company insiders. Executive Hulse William Frank IV sold 20,200 shares on 13 March 2026.

【Recent Insider Trades】

Disclosure Date Position Name Trade Date Buy/Sell Quantity Trade Price/US Dollar Total Amount/US Dollar
17 March 2026 Executive Maersk-Moller Kimberly 13 March 2026 Sell 6762 4.38 2.96万
17 March 2026 Executive Hulse William Frank IV 13 March 2026 Sell 2.02万 4.38 8.87万
12 March 2026 Executive Hulse William Frank IV 10 March 2026 Buy 7.49万 4.50 33.71万
12 March 2026 Executive DOUG RICE 10 March 2026 Buy 14.66万 4.50 65.99万
12 March 2026 Executive Maersk-Moller Kimberly 10 March 2026 Buy 2.16万 4.50 9.71万
18 February 2026 Executive Whitlow Ricci S 13 February 2026 Sell 6.20万 5.12 31.72万
10 November 2025 Executive Maersk-Moller Kimberly 6 November 2025 Sell 5.83万 7.42 43.23万
7 July 2025 Executive DOUG RICE 3 July 2025 Sell 1.27万 6.34 8.08万
26 June 2025 Executive Maersk-Moller Kimberly 24 June 2025 Sell 1.20万 5.96 7.17万
23 June 2025 Director BEHRENS M KATHLEEN、BIERMAN JAMES L、HAWKINS WILLIAM A、LAURENCIN CATO T、Olson Tiffany、PUHY DOROTHY E 18 June 2025 Buy 17.17万 6.47 111.06万

【Company Profile】

MiMedx Group, Inc. is incorporated in the state of Florida. The company is a pioneer and leader focused on helping humans heal with placental biopharmaceuticals. With more than ten years of experience helping clinicians manage chronic and difficult-to-heal wounds, MIMEDX is committed to providing a leading portfolio of wound care, burn, and surgical products for use in healthcare. The company’s vision is to become a leading provider of rehabilitation solutions worldwide through relentless innovation, to restore quality of life. With deep expertise, leading peer-reviewed data, and an extensive repository of additional scientific and real-world evidence in the field of placental biopharmaceuticals, MIMEDX develops and distributes placental tissue allografts manufactured using a patented proprietary process, which are applicable across multiple departments of healthcare.

Посмотреть Оригинал
На этой странице может содержаться сторонний контент, который предоставляется исключительно в информационных целях (не в качестве заявлений/гарантий) и не должен рассматриваться как поддержка взглядов компании Gate или как финансовый или профессиональный совет. Подробности смотрите в разделе «Отказ от ответственности» .
  • Награда
  • комментарий
  • Репост
  • Поделиться
комментарий
Добавить комментарий
Добавить комментарий
Нет комментариев
  • Закрепить